More on ENSC

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+85.3% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/16/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Ensysce Biosciences (NQ:ENSC)
Delayed: 0.52 -0.08 (13.33%)
Prev. Close $0.60  
Open$0.59 
52 Wk High$ 
52 Wk Low$ 
Day High$0.59 
Day Low$0.50 
P/E N/A  
EPS$ 
Volume490,554 

Friends, Peers and Foes (?): PLTR, RXT, CLRO, IOVA NTHI (more...)

Oct 16, 2026 06:04 AM Form 8-K/A Ensysce Biosciences, For: Aug 05
Sep 29, 2026 08:31 AM Form 8-K Ensysce Biosciences, For: Sep 25
Sep 24, 2026 08:02 AM Ensysce Biosciences submits Phase 2a protocol for CY200 to UK regulator
Sep 24, 2026 08:01 AM Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
Sep 15, 2026 09:16 AM Ensysce Biosciences presents at PainWeek, joins FDA psychedelics hearing
Sep 15, 2026 09:16 AM Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
Sep 14, 2026 08:01 AM Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Sep 2, 2026 08:32 AM Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
Aug 31, 2026 08:32 AM Ensysce completes enrollment in final stage of opioid study
Aug 31, 2026 08:31 AM Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
View All Articles

Entities mentioned with ENSC

View All Entities